特锐德 reported revenue of ¥6.64B for the period ended 2026-06-30, +6.1% year on year. Net income was ¥0.43B, a 6.5% net margin on a 26.8% gross margin. Free cash flow for the period was ¥0.44B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥6.64B | +6.1% |
| Gross profit | ¥1.78B | — |
| Operating income | ¥0.47B | — |
| Net income | ¥0.43B | +33.3% |
| Gross margin | 26.8% | Net margin 6.5% |
| Revenue Q/Q | +99.4% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥4.86B | 73.2% |
| R&D | ¥0.27B | 4.1% |
| SG&A | ¥0.95B | 14.3% |
| Tax & other | ¥0.04B | 0.6% |
| Item | Amount |
|---|---|
| Total assets | ¥24.87B |
| Total liabilities | ¥15.05B |
| Shareholders' equity | ¥9.82B |
| Equity / assets | 39.5% |
| Operating cash flow | ¥0.51B |
| Capital expenditure | ¥0.07B |
| Free cash flow | ¥0.44B |
| Cash conversion (OCF / net income) | -95% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神 ・ 鼎汉技术 ・ 华测检测 ・ 新宁物流
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies